Top Safest Stocks For 2018

QIm 73 years old, and I converted money in a traditional IRA to a Roth IRA in 2016. I know that I have until October 16 to undo the conversion and get back the money I paid in taxes. Will recharacterizing the IRA affect my required minimum distribution for 2017?

SEE ALSO: 6 Tax-Smart Ways to Lower Your RMDs in Retirement
A

Yes. Your required minimum distributions are based on your traditional IRA balance at the end of the previous year. When you convert traditional IRA money to a Roth, that money is removed from future RMD calculations (Roth IRAs are not subject to RMDs for the original owner).

However, if you take advantage of the opportunity to undo the conversion — and retrieve the tax you paid when you reported the converted amount as income — you restore the amount to your traditional IRA, and that increases your RMD. If all or a portion of the conversion is reversed, an adjustment to the December 31, 2016, balance needs to be made, thus increasing the 2017 RMD, says Jeffrey Levine, chief retirement strategist for Ed Slott and Co., an IRA consulting firm.

Top Safest Stocks For 2018: Sohu.com Inc.(SOHU)

Advisors’ Opinion:

  • [By Monica Gerson]

    Sohu.com Inc (NASDAQ: SOHU) is projected to report a quarterly loss at $0.57 per share on revenue of $406.50 million.

    Bank of Hawaii Corporation (NYSE: BOH) is expected to report its quarterly earnings at $0.99 per share on revenue of $149.88 million.

  • [By Belinda Cao]

    Sohu.com Inc. (SOHU), which sold a stake in its search unit to Tencent Holdings Ltd. (700), advanced 11 percent for the week to $72.06. It retreated 5.9 percent Sept. 20. Tencent, Chinas biggest Internet company by market value, paid $448 million for a 36.5 percent stake in Sohus Sogou unit last week and merge its own search service with Sogou.

  • [By Wayne Duggan]

    Sogou is Baidu’s biggest rival when it comes to mobile search engine market share. The app is owned by Sohu.com Inc (NASDAQ: SOHU), and its position as second fiddle to Baidu makes it most similar to Microsoft Corporation (NASDAQ: MSFT)’s Bing.

Top Safest Stocks For 2018: Quidel Corporation(QDEL)

Advisors’ Opinion:

  • [By Lisa Levin]

    Quidel Corporation (NASDAQ: QDEL) shares were also up, gaining 8 percent to $44.31. Piper Jaffray upgraded Quidel from Neutral to Overweight.

    Equities Trading DOWN

Top Safest Stocks For 2018: Snap Interactive, Inc. (STVI)

Advisors’ Opinion:

  • [By Vikram Nagarkar]

    According to recent reports, Snap Inc will now look to go public at a valuation of $19 billion to $22 billion, as it goes public under the ticker symbol SNAP on the New York Stock Exchange. Snap Inc’s move to slash its previous seemingly overambitious target of $25 billion comes across as a very good move. Well, there’s no denying the fact that the upcoming Snapchat IPO has generated a lot of investor interest – to the extent that some “overeager” investors even went ahead and bought shares of a similar sounding company,Snap Interactive (OTC:STVI), sending its shares 140% higher. And Snap Interactive’s relatively paltry $50 million market cap may have something to do with it. Be that as it may, Snapchat’s reported initial valuation target of $25 billion was way too ambitious, and there’s no lack of consensus on that front. However, even the scaled down $19 billion target may not be attractive enough.

Top Safest Stocks For 2018: Grupo Aeroportuario Del Pacifico, S.A. de C.V.(PAC)

Advisors’ Opinion:

  • [By Asit Sharma]

    In its fourth-quarter 2016 earnings filed on Feb. 23, Grupo Aeroportuario del PacificoSAB de CV(NYSE:PAC)capped a year of growth across several important metrics. The Mexican airport operator, which abbreviates its name to GAP, reported increases in revenue, profits, and domestic and international passenger traffic.

Top Safest Stocks For 2018: Bayer Aktiengesellschaft (BAYZF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Online Direct Sales – Once only consumer electronics and mobile handsets, the products it offers has grown to include 15 different categories, including home appliances and a wide array of general merchandise.

    In April, JD.com became a certified member of the American Apparel & Footwear Association (AAFA), the trusted public policy and political voice of the apparel and footwear industry, a first for a Chinese e-commerce company. In the first quarter of 2017, Avene, the leading demo-cosmetic brand for sensitive skin in European pharmacies, and three brands under Georgio Armani launched flagship stores on JD.com’s direct sales platform. JD Worldwide, a cross-border e-commerce platform set up in April 2015 to provide access to international brands (including those not available in China), has retail contracts with international brands such as Wal-Mart (NYSE:WMT), Phillips, Barcelona FC, and GNC (NYSE:GNC). Recently, it’s partnered with ASDA, a leading UK retailer under the Wal-Mart umbrella, as well as Bayer (OTCPK:BAYZF) and Cetaphil. As of March 2017, it operates 263 warehouses covering a gross floor area of 5.8 million square meters. GMV from the online direct sales business was RMB107.9 billion in the first quarter of 2017, up 42% from the first quarter of 2016. Net revenues from online direct sales increased by 40% in the first quarter of 2017 as compared to the first quarter of 2016. Fulfilled orders in the first quarter of 2017 were 477.1 million, an increase of 39% from 342.1 million in the same period in 2016. Fulfilled orders placed through mobile accounted for approximately 81% of total orders fulfilled in the first quarter of 2017, an increase of 56% compared to the same period in 2016.

    Online Marketplace – Third-party sellers offer products to customers and pay a commission to JD.com. They provide transaction processing and billing services on all orders on the online marketplace and leverage their own nationwide fulfillment infrastructu

  • [By SEEKINGALPHA.COM]

    We believe that the pharmaceutical sector has received too much negative attention. Despite the risks, a few companies offer good entry opportunities. In our previous article, we recommended Akorn. Today, we have analyzed Teva. We believe that the company is in a position to thrive in the generic market, and that it is priced very attractively. Yet, we don’t like management’s aggressive M&A strategy. We don’t like very aggressive companies since large acquisitions rarely create value for the shareholders. Contributors argue that Teva has overpaid for Actavis (its latest and largest acquisition) by at least $14B. This does not surprise us since most M&A deals are too expensive. Previous corruption issues add further doubts. Unfortunately, there is no amount of profit that can convince us to invest in a company where we do not like the management. We have sold our positions in Bayer (OTCPK:BAYZF) for similar reasons. We like Bayer, but we have sold our shares because of the Bayer-Monsanto (NYSE:MON) acquisition.

  • [By SEEKINGALPHA.COM]

    And this is pretty important ground. Hepatocellular carcinoma can be managed with local therapy (surgery, embolization, etc.), but at its most advanced stages, the options quickly start to thin out. For a decade, the only option in systemic therapy was Bayer’s (OTCPK:BAYZF) sorafenib. Recently, the effective systemic treatment armamentarium was doubled with the approval of regorafenib for second-line therapy.

  • [By SEEKINGALPHA.COM]

    Other R&D products in Regeneron’s pipeline that we are interested in

    Fasinumab: Antibody against nerve growth factor, being developed for pain treatment like osteoarthritis. It is partnered with Teva Pharmaceutical (NASDAQ:TEVA) (for osteoarthritis, in phase 3), and is also being developed for treatment of chronic back pain. It is licensed to Mitsubishi Tanabe for the Japan territory. REGN2222: For prevention of RSV virus infection in infants, competing with Synagis from AstraZeneca (NYSE:AZN). Nesvacumab: Angiopoetin 2 antibody, being tested in combination with Eylea (in phase 2, partnered with Bayer (OTCPK:BAYZF)). Rinucumab (anti-PDGF): Being tested in treatment of wet AMD in combination with Eylea. Phase 2 trial was not successful, but the treatment duration was less (only 12 weeks versus 24 weeks for rival Ophthotech (NASDAQ:OPHT)). 28-week and 52-week data will be released later. With Ophthotech’s phase 3 failure with Fovista, we are bullish on Rinucumab’s commercial potential in wet AMD. Immuno-oncology pipeline: Checkpoint inhibitors and novel CAR-T; still in early stage.

    Click to enlarge

Leave a Reply

Your email address will not be published. Required fields are marked *